InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
winner06 Free
05/10/18 12:33 PM
profile icon
la_trader Free
05/02/18 8:03 PM
profile icon
Renee PremiumMember
09/19/17 9:06 AM
profile icon
upanddown1950 Free
08/19/16 5:32 PM
profile icon
riseup Free
08/15/16 9:25 PM
profile icon
riseup Free
08/11/16 7:35 PM
profile icon
ThoroughBread Free
08/11/16 5:42 PM
profile icon
Termite7 Free
08/08/16 1:18 PM
profile icon
upanddown1950 Free
08/07/16 1:32 AM
profile icon
upanddown1950 Free
07/31/16 1:14 PM
profile icon
upanddown1950 Free
07/29/16 7:10 PM
profile icon
Sirpeter PremiumMember
07/28/16 10:09 AM
profile icon
upanddown1950 Free
07/27/16 10:23 PM
profile icon
riseup Free
07/27/16 4:45 PM
profile icon
BigJuan PremiumMember
07/27/16 3:26 PM
profile icon
ThoroughBread Free
07/27/16 10:29 AM
profile icon
BLOODGUARD Free
07/27/16 10:24 AM
profile icon
TFALL68 Free
07/27/16 10:02 AM
profile icon
BigJuan PremiumMember
07/27/16 9:53 AM
profile icon
TFALL68 Free
07/27/16 9:16 AM
profile icon
Pink Current Free
07/27/16 8:02 AM
profile icon
stealthfighter Free
07/27/16 8:00 AM
profile icon
TFALL68 Free
07/27/16 7:04 AM
profile icon
upanddown1950 Free
07/27/16 2:15 AM
profile icon
upanddown1950 Free
07/26/16 9:10 PM
profile icon
riseup Free
07/26/16 5:56 PM
profile icon
Prince Goro Free
07/26/16 11:17 AM
profile icon
BigJuan PremiumMember
07/26/16 10:24 AM
profile icon
Prince Goro Free
07/26/16 10:00 AM
profile icon
Prince Goro Free
07/26/16 9:27 AM
profile icon
Prince Goro Free
07/26/16 8:57 AM
profile icon
Prince Goro Free
07/26/16 8:40 AM
profile icon
ProTrader4000 Free
07/25/16 8:38 PM
profile icon
ProTrader4000 Free
07/25/16 8:37 PM
profile icon
Clark6290 Free
07/25/16 12:49 PM
profile icon
LA_BoSko Free
07/25/16 12:16 PM
profile icon
Executive Order Terminated
07/25/16 12:43 AM
profile icon
Zalmy Free
07/24/16 11:49 PM
profile icon
Clark6290 Free
07/23/16 3:29 PM
profile icon
l2 hunter Free
07/23/16 2:42 PM
profile icon
riseup Free
07/23/16 11:20 AM
profile icon
Clark6290 Free
07/23/16 2:21 AM
profile icon
SmartTrader10 Free
07/23/16 1:25 AM
profile icon
BERKSHIRE AGENT Free
07/23/16 12:34 AM

Newcardio, Inc. (NWCI) RSS Feed

Followers
29
Posters
98
Posts (Today)
0
Posts (Total)
568
Created
10/09/08
Type
Free
Moderators


 

OTC Pink No Information

Corporate Headquarters
NewCardio, Inc.

103 Carnegie Center, Suite 300
Princeton, NJ 08540
877.332.4324

  Received Period Ending Size Report
8-K Jan 10, 2012 Jan 1, 2012 18.2 KB PDF    RTF    HTML    XLS
8-K Dec 29, 2011 Dec 22, 2011 15.5 KB PDF    RTF    HTML    XLS
8-K Dec 6, 2011 Nov 30, 2011 12.2 KB PDF    RTF    HTML    XLS
10-Q Nov 14, 2011 Sept 30, 2011 1.7 MB PDF    RTF    HTML    XLS
8-K Oct 21, 2011 Oct 17, 2011 10.8 KB PDF    RTF    HTML    XLS
8-K Oct 12, 2011 Oct 5, 2011 19.9 KB PDF    RTF    HTML    XLS
10-Q/A Aug 25, 2011 Jun 30, 2011 1.3 MB PDF    RTF    HTML    XLS
NT 10-Q Aug 16, 2011 Jun 30, 2011 15.2 KB PDF    RTF    HTML   
10-Q Aug 16, 2011 Jun 30, 2011 599.9 KB PDF    RTF    HTML    XLS
8-K Jun 20, 2011 Jun 17, 2011 23.9 KB PDF    RTF    HTML    XLS
NewCardio, Inc. (OTC BB: NWCI), a cardiac diagnostic and services company, develops proprietary platform technology to dramatically improve accuracy and significantly increase the diagnostic value of the standard 12-lead electrocardiogram (ECG). NewCardio's solutions incorporate novel, state-of-the-art technology that management believes will significantly improve the diagnostic accuracy and precision of the analysis and use of signals from ECGs, without disrupting the well-established 12-lead ECG practice. The Company's technology is based on a three-dimensional approach to modeling cardiac activity using standard 12-lead ECG signals. Accordingly, New-Cardio is poised to, over time, derive value from each of the 375 million ECGs performed annually around the world. 
NewCardio is applying its proprietary technology to assess cardiac safety of new drugs in development and to improve clinical diagnosis and assessment of patients with suspected and established heart disease. Management believes this technology represents a highly significant advance and has the opportunity to be a disruptive force in markets that exceed $4.5 billion in aggregate annually

Management includes thought leaders from the Intel, pharmaceuticals, medical devices (St. Jude Medical), Core Labs and the investment industry. The Company believes its broad-based management team is particularly wellsuited to advance the Company's goals and develop its technology into a set of essential diagnostic tools for the ECG segment of the cardiac diagnostics industry.

Key initial applications include cardiac toxicity (lethal arrhythmias) determination during new drug development,and cardiac status for acute and chronic patient management.  
The FDA requires that all new drugs be tested for potential cardiac toxicity early in development. Current methods are costly and timeconsuming.  New drugs are often tested on more than 1,000 subjects, with ECGs collected at multiple time points. Using NewCardio's 3D approach, drug sponsors and CROs can automate this process, significantly reducing the cost and accelerating the test times for drugs in development. A leading independent industry analyst estimated this market to exceed $650 million annually. 
NewCardio's products could change the way patients with chronic heart conditions will monitor their disease outside the acute care setting. The Company is developing a hand-held device that could transmit the ECG data and synthesized 12-lead data to doctors remotely. This will enable complete cardiac assessment, in contrast to current devices that enable arrhythmia monitoring only. A recent study by Frost & Sullivan estimated this market to approach $2 billion. 
The Company believes its diagnostic tools will substantially improve the accuracy and timeliness of the diagnosis and response to patients arriving at Emergency Departments with suspected acute coronary syndromes (heart attack and related conditions). NewCardio's My3KG will enable doctors to diagnose acute coronary syndromes more quickly and accurately than with traditional methods, possibly saving thousands of lives annually and reducing costs associated with unnecessary hospital admissions. With more than 70 million ECGs performed in ERs each year in the U.S. alone at an average (current) reimbursement of $30 each, this market could exceed $2 billion annually at current reimbursement rates.
  NewCardio was selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property (IP). It is one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB's proprietary IP business intelligence platform.
NewCardio Receives Notice of Allowance for Vital Patent for Cardio3KG(TM) Represents Core Patent for NewCardio's 3-D ECG platform technology
SANTA CLARA, Calif., Feb. 25 /PRNewswire-FirstCall/ -- NewCardio, Inc. (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent covering technology relating to NewCardio's Cardio3KG solution (formerly VisualECG or Visual3Dx). This represents the core patent for NewCardio's anticipated emergency/urgent care solution, Cardio3KG.
The Cardio3KG solution is comprised of a set of algorithms and tools that provide a comprehensive method to assess cardiac electrical activity in time and space, and to extract additional 3-dimensional information from standard 12-lead ECG signals. This may enable Cardio3KG to assess potentially fatal diseases and conditions, including acute coronary syndrome, with greater speed and accuracy than possible by standard ECG.
When issued, together with US patent 7,266,408,this will be NewCardio's second U.S. patent covering broad aspects of the Company's 3-D ECG platform technology and, particularly, specifics of Cardio3KG, the first solution targeted to take full advantage of this intellectual property.
"This action by the USPTO reinforces our continuing investment in and commitment to our novel cardiovascular diagnostic platform technology, which provides 3-D analysis of the heart's electrical activity," stated NewCardio's CEO, Branislav Vajdic, PhD. "We believe the Cardio3KG solution will substantially improve the accuracy and timeliness of response and diagnosis for patients arriving at emergency departments with heart attack symptoms and related conditions. NewCardio's Cardio3KG will enable doctors to diagnose acute coronary syndromes more quickly and accurately than with traditional methods, possibly saving thousands of lives annually and reducing costs associated with unnecessary hospital admissions. We also believe Cardio3KG, along with QTinno™ and CardioBip™, represent important steps forward in validating our 3-D ECG platform's ability to improve cardiac diagnosis, clinical outcomes, and drug safety. We are pleased that patent offices in both the US and Europe are acknowledging our proprietary claims to our core technologies."
 

PATENT PROTECTED

App Number/
Filing Date
 
Brief Summary
(Products Covered)
Status
PCT/
YU2004/
00020
08/20/04
Cordless recording and telecommunication of three special ECG leads and their processing (CardioBip)
US Patent No. 7,647,093 issued 01/12/10.
EU Certificate of Patent Grant EP1659936 issued 12/26/2007. EU Patent active in DE, ES, FI, FR, IT, GB, GR, PL. Other national phases are being processed.
International Application now being examined in China, Japan, Korea and the European Union (EU).
PCT/
US2005/
001239
01/16/ 05
Visual 3-D  presentation of ECG data (my3KG, QTinno)
International Application now being examined in the China, Japan, Korea and the European Union (EU)
US 11/
036,930
1/16/04
Visual 3-D  presentation of ECG data (my3KG, QTinno)
US Patent No. 7,266,408 issued 09/04/07.
PCT/US2005/001239 International Application.
US 11/
848,221
1/16/04
Visual 3-D  presentation of ECG data (my3KG, QTinno)
Filed as divisional US Patent Application on 08/30/07. Divisional with respect to 11/036,930, filed on 1/16/04.
US PTO notice of all-claim allowance on 1/28/10. US patent 7,751,875 issued on July 6, 2010.
PCT/
US2008/
009308
07/31/07
Quantitative assessment of cardiac electrical events (QTinno)
Priority to US Provisional Application filed 08/01/07.
US Patent
Application
Device and methods for evaluating cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 07/31/08. Application # US 12/184,068. Priority to US Provisional Application filed 08/01/07.
US Patent
Application
System for quantitative assessment of cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 06/12/09. Application # US 12/484,153.
US Patent
Application
Method for quantitative assessment of cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 06/12/09. Application # US 12/484,156.

                     US Patent
Application
Electrocardiographic Monitoring System and Method Using Orthogonal Electrode Pattern (CardioBip)
US Patent Application filed with US PTO on 07/31/09. Application # US 12/534,064.
US Patent
Application
ECG Reconstruction For Atrial Activity Monitoring And Detection (CardioBip)
US Patent Application filed with US PTO on 11/05/09. Application # US 12/613,488.
US Patent
Application
Method for Automated EKG Analysis (my3KG)
US Patent Application filed with US PTO on 11/06/09. Application # US 12/614,352.
US Patent
Application
System for Automated EKG Analysis (my3KG)
US Patent Application filed with US PTO on 11/06/09. Application # US 12/614,354.
US Patent
Application
System and Method for Automated EKG Analysis (my3KG)
US Patent Application filed with US PTO on 11/06/09. Application # US 12/614,361.
US Provisional Patent Application
Alternative Markers For Quantitative Assessment of Cardiac Electrical Events (QTinno)
US Provisional Patent Application filed with US PTO on 12/15/09. Provisional Application # US 61/286,763.
 
US Patent Application
Atrial Fibrillation Detection based on Absence of Consistent P-Loops in Averaged Vectorcardiogram
(CardioBip)
US Patent Application filed with US PTO on 1/26/10. Application # US 12/694,236.
US Patent Application
Methods and apparatus for quantitative assessment of cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 1/28/10. Application # US 12/695,128.
US Patent Application
Visual 3-D  presentation of ECG data (my3KG, QTinno)
Filed as divisional US Patent Application in 3/17/10. Divisional with respect to 11/036,930, filed on 1/16/04. Application # US 12/726,168.
PCT
Systems and Methods For Quantitative Assessment of Cardiac Electrical Events (QTinno)
Application No.:  PCT/US2010/036084
International Filing Date:  May 25, 2010
Priority of 12/484,153 and 12/484,156 filed 6/12/09
PCT
Electrocardiographic Monitoring System and Method Using Orthogonal Electrode Pattern (CardioBip)
Application No.:  PCT/US2010/44013
International Filing Date:  July 30, 2010
Priority to US Patent Application filed with US PTO on 07/31/09. Application # US 12/534,064.

                         PCT
Automated EKG Analysis (my3KG)
PCT/US2010/052373
Filed 10/12/10
Priority of: 12/614,352, 12/614,354  and 12/614,361
Title: AUTOMATED EKG ANALYSIS
PCT
ECG Reconstruction For Atrial Activity Monitoring And Detection (CardioBip)
Application No.:  PCT/US10/55174, Filed: 11/2/10
(Priority: U.S. Application No.  12/613,488; Filed: 11/5/09)
PCT
Alternative markers for quantitative assessment of cardiac electrical events (QTinno)
Application No.:  PCT/US10/60041, Filed: 12/13/10. Priority to divisional application # US 61/286,763 filed on 12/15/09.
US Patent Application
Method and apparatus for quantitative assessment of cardiac electrical events (QTinno)
US Patent Application filed with US PTO on 01/03/2011. Application # US 12/983,451. Divisional to application # US 12/184,068. Priority to US Provisional Application filed 08/01/07.
PCT
Methods and apparatus for quantitative assessment of cardiac electrical events (QTinno)
Application No.:  PCT/US2011/21739, Filed: 1/19/11. Priority of US Patent Application # US 12/695,128 filed 1/28/10.
PCT
Atrial Fibrillation Detection based on Absence of Consistent P-Loops in Averaged Vectorcardiogram
(CardioBip)
Application No.:  PCT/US2011/22455, Filed: 1/25/11. Priority of US Patent Application filed with US PTO on 1/26/10. Application # US 12/694,236.
    

 

 

Newcardio Inc, has been invited to present the results of a recent QTinno ® performance study at an upcoming conference entitled "Cardiovascular Safety in Drug Development: State-of-the-Art Assessments," sponsored by the U.S. Food and Drug Administration (FDA), the Cardiac Safety Research Consortium (CSRC) and the Heart Rhythm Society (HRS). The conference will be held in Washington, DC, on April 14-15, 2011.

Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We were delighted with the significant improvement in measurement variability and study power that we observed in this investigation. We look forward to sharing this exciting data at this important conference, which is attended by cardiovascular safety experts from regulatory bodies, pharmaceutical companies, clinical research organizations and academia. The improvement conferred by our new automated ECG selection algorithm offers sponsors the opportunity to reduce the number of subjects in a study without sacrificing study power, which may result in substantial cost savings. The new algorithm is a powerful extension of our platform technology, and further demonstrates NewCardio's ability to add value to every ECG."

Vincent Renz, CEO of NewCardio, commented, "These study results represent yet another important and substantial technological innovation for QTinno that further differentiates QTinno from competition and solidifies QTinno's position as the industry's leading automated solution for drug safety studies. This is further evidence that NewCardio will continue to enhance QTinno in order to eliminate the manual, labor intensive procedures employed in the current cardiac safety methodologies, which typically affect the drug sponsors through longer timelines, higher costs and from our findings, lower quality. We believe that our latest innovation, intelligent ECG extraction, will provide additional gains that will allow the pharmaceutical industry to complete higher quality cardiac safety analysis faster, more reliably, and at significantly lower cost."

www.b2i.us/profiles/investor/ResLibraryView.asp


NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics with Acute Myocardial Infarction.

The presentation will be made at the 71st Annual ADA Scientific Sessions to be held in San Diego, CA, June 24-28, 2011. In addition, the ADA has selected this presentation to be showcased in the Guided Audio Poster Tour, which features expert moderators that share their perspectives with attendees, highlighting novel and important developments in the field.

Dr. Ihor Gussak, MD, PhD, NewCardio's Chief Medical Officer, commented, "We are delighted to present our study results at this important gathering of diabetes experts, and particularly pleased that the ADA program committee chose to feature our presentation in a moderated poster session. Accurate and timely AMI diagnosis is a matter of great concern for diabetologists, and we believe our results show that my3KG can play a major role in solving it. The moderated poster session provides the opportunity to present our results directly to leading diabetes experts, and have one-on-one interactions that will allow us to discuss and explain the importance of our results in detail."

www.b2i.us/profiles/investor/ResLibraryView.asp


Breakthrough Technology

The standard 12-lead electrocardiogram (ECG or sometimes called EKG) is a diagnostic recording of cardiac electrical activity over time. The 12-lead ECG is cardiology's most frequently used screening and diagnostic tool. Over 200 million ECGs are obtained in the developed world each year, making it the most commonly performed cardiovascular diagnostic test. The ECG has a central role in screening and diagnosis of acute coronary syndromes (heart attack) and many other common forms of heart disease, and often provides the primary basis for critical therapeutic decisions.

Unknown by many, the standard ECG contains latent information about cardiac electrical activity that in total represents the three dimensional (3D) operation of the heart. However, today's standard 12-lead ECG merely represents that data as a series of 2-dimensional time and voltage readings, which must be synthesized into a 3D model of the heart operation by a clinician. It is very difficult, and in the case of some critical parameters impossible, for humans to perform this 3D synthesis in their mind.

NewCardio has developed a new patented and patent pending technology which can process this standard ECG data, and utilize and present it an easy to read format with additional 3D clinically significant diagnostic information. Importantly, no change in clinician practice of how ECG data is collected. Simply said - NewCardio does not change the standard practice for ECG collection.

The past 40 years have brought us remarkable gains in computational power. This creates an opportunity to extract substantially more diagnostically valuable information from the ECG signal. By continuing to develop appropriate mathematical algorithms and software, NewCardio believes that its proprietary 3D approaches can significantly enhance the ECG's diagnostic utility, reduce its complexity, and improve its ease of use for the medical professional. Results of first medical trials of NewCardio's technology at Harvard University Medical School and elsewhere indicate initial results to be very encouraging.


INVESTMENT HIGHLIGHTS

  • The Company's technology uses the widely accepted, standard 12-lead ECG input and displays the signals in a three-dimensional output, providing significantly increased sensitivity accuracy and precision and the capability to automate what has historically used more costly and labor-intensive manual or semi-automated processes.

 

  • The Company is developing three unique solutions using its core platform technology, addressing three distinct and rapidly growing segments of the industry and creating planned revenue diversity.

 

  • NewCardio's first solution, QTinno™, offers the first realistic opportunity for fully automated testing in Thorough QT (TQT) and cardiac safety clinical trials. The FDA requires that all new drugs be tested (TQT) for potential cardiac toxicity early in clinical development. Current testing methods are costly and time-consuming. Management believes QTinno will significantly increase accuracy and productivity of the cardiac toxicity assessment.

 

  • The Company's initial studies have confirmed that QTinno delivers virtually identical accuracy to the existing semi-automated "gold standard", but at far lower cost and with fully automated tests completed in hours, as compared to weeks of labor-intensive manual review by cardiologists when semi-automated approaches are used.

 

  • The Company has assembled a team of talented and experienced entrepreneurs and business managers, including leaders from various industries like technology, pharma, academics, and a wide range of other scientists and professionals. The Company's new chairman is the most-prolific inventor of electrical medical devices in the world; virtually every ICD (Implantable Defibrillator) manufacturer licenses patents covering technology invented by the chairman.

Leadership and Advisors



The Company has assembled a team of talented and experienced entrepreneurs and business managers, including leaders from various industries like technology, pharma, academics, and a wide range of other scientists and professionals.

 

Management Team

NewCardio has assembled an experienced and skilled management team which has proven their ability to create new products and build new enterprises.

Jess Jones, M.D. - Chief Executive Officer

Dr. Jones has been a member of the Company's Board of Directors since December 2008 . From 2006 to December 2010 Dr. Jones worked with Vision Capital Advisors, LLC in New York City as the Director of Healthcare Investing, analyzing investment opportunities in the biotechnology, pharmaceutical, medical technology, and medical services fields, and assisted companies in implementing their business plans. From 2001 to 2007, Dr. Jones attended Columbia College of Physicians & Surgeons in New York City , where he received his medical degree in May 2007 . Additionally, Dr. Jones earned a BA degree from the University of Utah in 2001 and an MBA from Columbia Business School in May 2007.

Greg Sadowski - Chief Operating Officer

Mr. Sadowski has served as Senior Vice President, Client Services for NewCardio since October 2008 . In that position, he has been responsible for preparing, delivering and supporting the NewCardio cardiovascular diagnostic technology solutions, including the Professional Services, Information Technology, Customer Care and Quality Assurance groups. From October 1997 to October 2008 , Mr. Sadowski worked with eResearchTechnology (eRT), where he served on the Executive Management Team as Senior VP of eRT's Electronic Patient Reported Outcomes (ePRO) business.


Board of Directors

Michael E. Hanson

Mr. Hanson is a founding partner of Barnard Life Sciences, a healthcare consulting company founded in 2001. From 2004 to 2009, Mr. Hanson was a member of the board of directors, compensation and audit committees, of Indevus Pharmaceuticals. From 2002 to 2006, Mr. Hanson was a member of the board of directors, compensation and audit committees, of GlycoGenesis, an oncology-focused company. From 1998 to 2001, he was a member of the board of directors, compensation and audit committees, of MGI Pharma, Inc., which was later purchased by Eisai Pharmaceuticals. Mr. Hanson also serves on the board of directors of Z-92 Pharma and Eleos, Inc., and is also a member of Pearl Street Ventures, a venture capital firm that specializes in healthcare companies and Cardinal Equity Partners, a private equity firm. Previously, Mr. Hanson spent 25 years in positions of increasing responsibility at Eli Lilly and Company. He served as President and General Manager of Eli Lilly Japan KK from 1989 to 1992. He subsequently served as Vice President of Lilly Research Laboratories with responsibilities for the Medical Department. He culminated his Lilly career as President of the Internal Medicine Business Unit which included all cardiovascular and oncology products and became a member of the Eli Lilly and Co. Operations Committee (the senior management group of the company at that time). Mr. Hanson received a B.S. in Pharmacy from North Dakota State University and an M.S. in Hospital Pharmacy Administration from the University of Minnesota, and attended the Advanced Management Program at Harvard Business School.

Jess Jones, MD

Director since December 1, 2008. From 2006 to present Dr. Jones has worked with Vision Capital Advisors, LLC as the Director of Healthcare Investing, analyzing investment opportunities in the biotech, pharmaceutical, medical technology, and medical services fields, and assisted companies in the implementation of their business plans. From 2001 to 2007, Dr. Jones attended Columbia College of Physicians & Surgeons, where he received his medical degree in May 2007. In 2005, while attending Columbia Medical School, Dr. Jones was awarded an American Heart Association-Medical Student Research Fellowship to study post-stroke inflammatory mediators in the Department of Neurosurgery. Additionally, Dr. Jones earned a BA degree from the University of Utah and an MBA from Columbia Business School.


Executive Consultants

NewCardio's Executive consultants are intimately involved with day to day activities and are spending significant portion of their time working with the Company.

 

Vincent Renz

Vinnie has more than 26 years of experience in the information technology industry, specifically in the development and commercialization of technology products and services. He previous worked at ClinPhone, the world's leading Clinical Technology Organization which was acquired by PAREXEL International Corporation, a leading global biopharmaceutical services organization. At ClinPhone, Mr. Renz served as Chief Operating Officer. Previously, he worked for eResearchTechnology, Inc. as the Executive Vice President and Chief Technology Officer and played a key role in building eResearchTechnology's clinical technology business. Mr. Renz was also instrumental in developing the global business development and client services infrastructure to support the company's rapid growth and profitability. Mr. Renz earned an M.B.A. in Management Information Systems from Indiana University and a B.B.A. in Finance from the University of Notre Dame.

Samuel George, MD, FACC, JD - Senior Medical Consultant

Sam was formerly Director of Medical Affairs at CV Therapeutics, a cardiology faculty member and Director of the Cardiac Study Program at Duke University Medical Center, and an Established Investigator of the American Heart Association. He was also a biomedical patent attorney with Latham & Watkins LLP and is registered to practice before the U.S. Patent and Trademark Office. He holds M.D. from Washington University (St. Louis) and JD from Duke University.


Technology Advisors

The role of the Technology advisory Committee (TAC) is to participate in setting technology development directions and provide expert opinion and help with the current technical issue.
 

Gari Clifford, Ph.D.

Currently is a Principal Research Scientist at the Harvard-MIT Division of Health Sciences, where he is the engineering manager of a National Institute of Health (NIH)-funded research program "Integrating Data, Models, and Reasoning in Critical Care," and a major contributor to the well-known Physionet Research Resource. He has worked in industry on the design and production of several FDA-approved medical devices. Dr. Clifford has taught at Oxford, MIT, and Harvard, and is currently an instructor of Biomedical Engineering at MIT. He is on the editorial boards of Biomedical Engineering Online and the Journal of Biological Systems and has authored the definitive textbook "Advanced Methods and Tools for ECG Data Analysis," which is used by advanced students throughout the world in medical and engineering colleges and universities.

Branislav Vajdic, Ph.D.

Branislav is a founder of NewCardio and provides the strategic direction for the firm as its CEO. He is a proven creator of new technologies and has commercialized them into industry leading products. A 23 year veteran of Intel where he held various senior management positions including directing the Pentium & Flash memory development teams. He led a small team that designed Intel's first flash memory product and he holds several early Flash memory design patents. Branislav received a Ph.D. in electrical engineering from the University of Minnesota.

Professional Advisors


Morrison & Foerster LLP

Worldwide IP Attorney


Wilson Sonsini Goodrich & Rosati LLC

Corporate Attorney


Russell Bedford Stefanou Mirchandani LLP

Auditors

 

 

 

 

 

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
  The following table sets forth the number of shares of common stock beneficially owned as of March 21, 2011 (the "Beneficial Owner Date") by (i) those persons or groups known to us to beneficially own more than 5% of our common stock; (ii) each director; (iii) each executive officer; and (iv) all directors and executive officers as a group. The information is determined in accordance with Rule 13d-3 promulgated under the Exchange Act based upon information furnished by persons listed or contained in filings made by them with the SEC or by information provided by such persons directly to us. Except as indicated below, each of the stockholders listed below possesses sole voting and investment power with respect to their shares and the address of each person is c/o NewCardio, Inc., 2350 Mission College Boulevard, Suite 1175, Santa Clara, California, 95054.
 

Name of Beneficial Owner
 
Common Stock Beneficially Owned
(1)
   
Percentage of Common Stock
(2)
 
Branislav Vajdic, Ph.D. (3)
    9,208,910       27.88  
Vincent W. Renz, Jr. (4)
    1,237,137       3.89  
Richard Brounstein (5)
    690,000       2.19  
Mark W. Kroll, Ph.D., FACC, FHRS (6)
    419,896       1.34  
Robert N. Blair, M.Inst.P. (7)
    830,843       2.67  
James A. Heisch (8)
    228,790       *  
Jess Jones, M.D.
    0       *  
Patrick Maguire, M.D., Ph.D. (9)
    177,956       *  
Michael Hanson (10)
    145,877       *  
Ihor Gussak (11)
    786,705       2.49  
Dorin Panescu (12)
    755,777       2.39  
Greg Sadowski (13)
    429,208       1.38  
                 
All officers and directors as a group (12 persons)
    14,911,099       39.48  
 

 

Please keep this board about NWCI only! 

 

 

 

 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
NWCI Latest News
  • No Recent News Available for this company!
New Post